查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138358

全球军团菌检测市场-2022-2029

Global Legionella Testing Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

主要驱动因素是肺炎和军团菌相关疾病的发病率不断上升，对快速和先进诊断技术的需求不断增加，以及细菌学检测技术的进步。

意识的提高和研发支出的增加正在推动全球市场的增长。

医疗保健意识的提高和投资的增加正在推动全球市场的增长。例如，西区公共卫生培训中心参与开展退伍军人疾病预防培训。由 CDC 国家环境健康、免疫和呼吸系统疾病中心、国家公共卫生实验室网络、亚利桑那大学公共卫生学院 Mel 和 Enid Zuckerman 以及亚利桑那大学西部区域培训中心开发的军团菌水管理计划培训的此外，增加对医疗保健的投资也在振兴全球市场。例如，根据欧洲製药商协会联合会的数据，2000 年製药业的生产为欧洲经济贡献了 1275.04 亿欧元，2010 年为 1997.3 亿欧元，2019 年为 2932.13 亿欧元，2020 年达到 310 亿欧元.此外，研发支出在 2000 年为 178.49 亿欧元，2010 年为 279.2 亿欧元，2019 年为 377.54 亿欧元，2020 年为 3900 亿欧元。

与检测相关的高昂成本和严格的政府立法限制了军团菌检测领域的发展。

发展中国家和欠发达国家的可支配收入短缺、诊断测试敏感性问题、与测试相关的高成本以及严格的政府法律。与测试相关的高成本可能会阻碍市场增长。例如，典型的费用从小型牙科诊所和从业者的 200 英镑到中型疗养院的 500 英镑不等。严格的政府法律的存在也阻碍了市场。例如，COSHH（对健康有害物质的控制条例）提供了一个行动框架来管理各种有害物质的风险，包括生物製品（如军团菌）。它是识别和评估风险并实施必要的措施来控制所有风险。自 L8 批准的实践守则（第 3 版）（ACOP）发布以来，商业机构和家庭机构的业主都必须评估其居住者暴露于军团菌的风险。

行业分析

《全球军团菌检测报告》根据各种行业因素（包括波特五力、创新、新产品发布、定价等）对市场进行了深入分析。

COVID-19 影响分析

此后为防止 COVID-19 进一步传播而实施的各种限制和法规已经影响了全球市场，使得开展影响市场的军团菌检测变得困难。此外，大流行还影响了许多发达和新兴经济体，使军团菌检测市场在爆发期间难以增长。

全球军团菌检测报告将提供大约 40 多个市场数据表、45 多个数字和大约 200 页的访问权限。

内容

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 提高认识
      • 研发费用增加
    • 限制因素
      • 与检查相关的高成本
      • 严格的政府政策
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按测试类型

  • 尿抗原检测 (UAT)
  • 培养方式
  • 直接荧光免疫分析 (DFA)
  • 聚合□炼式反应 (PCR) 方法
  • 其他

第 8 章. 按应用程序

  • 临床检查方法
  • 环境检查法

第 9 章抗生素

  • 阿奇霉素
  • 利福平
  • 奎诺酮类
  • 其他

第 10 章，最终用户

  • 医院
  • 诊断中心
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 13 章公司简介

  • 雅培
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Albagaia Ltd
  • Aquacert Ltd
  • Becton, Dickinson and Company
  • BioMerieux SA
  • Idexx Laboratories Inc.
  • Merck Millipore
  • Pacific Water Technology
  • Phigenics LLC
  • Qiagen NV
  • Thermo Fisher Scientific Inc.

第14章 DataM

简介目录
Product Code: DMCD2149

Market Overview

Legionella Testing Market is expected to grow at a CAGR of 9.7% during the forecasting period (2022-2029).

Legionella is a bacterium that causes a severe form of pneumonia called Legionnaires disease or flu-like illness. Legionella testing aids in detecting the presence of bacteria to help diagnose the cause of a person's pneumonia.

Market Dynamics

The major driving forces are the rising incidence of pneumonia and legionella-related illnesses, increasing demand for rapid and advanced diagnostic techniques, and technological advancements in bacterial testing.

The increasing awareness and growing spending on research and development are driving the global market growth.

The growing awareness and increased investment in healthcare are fueling global market growth. For instance, Western Region Public Health Training Center is involved in providing training for Preventing Legionnaires' Disease: A Training over Legionella Water Management Programs, which is developed by the CDC's National Center for Environmental Health, Immunization and Respiratory Diseases, National Network of Public Health Institutes, College of the Public Health University of Arizona Mel and Enid Zuckerman and The Western Region Training Center at the University of Arizona. Furthermore, the increasing investment in healthcare is also fueling the global market. For instance, according to the European Federation of Pharmaceutical Industries and Associations, in 2000, the production from the pharmaceutical industries contributed €127,504 million to Europe's economy, which reached €199,730 million in 2010, €293,213 million in 2019 and €310,000 million in 2020. Furthermore, the R&D expenditure was €17,849 million in 2000, €27,920 million in 2010, €37,754 million in 2019 and €39,000 million in 2020.

The high costs associated with the tests and strict government laws will restrain the global Legionella Testing growth.

The insufficient disposable income in developing and underdeveloped countries, issues in sensitivity of diagnostic tests, high costs associated with the tests, and strict government laws. The high costs associated with the tests will likely hamper the market growth. For instance, typical costs range from £200.00 for a small dental or GP practice to £500.00 for a medium-sized care home. The presence of strict government laws is also hindering the market. For instance, The Control of Substances Hazardous to Health Regulations (COSHH) gives a framework of actions to control the risk from a range of hazardous substances, including biological agents (e.g., Legionella) - to identify and evaluate the risk and implement any necessary measures to control any risk. Since the L8 Approved Code of Practice (3rd edition) (ACOP) was published, there has been a requirement for landlords of both business premises and domestic premises to evaluate the risks from exposure to Legionella to their tenants.

Industry analysis.

The global legionella testing report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing Etc.

COVID-19 Impact Analysis

Different restrictions and regulations forced to prevent further COVID-19 infection spread have impacted the global market since, making it difficult for people to perform legionella testing affecting the market. Furthermore, the pandemic has also affected many developed and developing countries economies, making it difficult for the legionella testing market to grow during the outburst.

Segment Analysis

Urinary antigen testing is expected to have a large share of the Legionella Testing market during the forecast period (2022-2029).

The Urinary Antigen Test segment is expected to grow rapidly over the forecast period (2022-2029). UAT is a diagnostic tool that offers same-day results. Further, UAT is not resource-specific and technically intensive like the culture tests. Since the urinary antigen test does not require respiratory fluid samples, sensitivity issues are also reduced. Thus, UAT remains the test of choice for clinicians and diagnostic experts primarily because of its ease of handling, rapid testing advantage, increased sensitivity, and specificity. For instance, according to the CDC, it has 70-100% sensitivity and 95-100% specificity. Also, the presence of research and development activities on urinary antigen tests is driving the market. Furthermore, a research study on the novel Legionella urinary antigen test kit for diagnosing Legionella pneumonia showed that it could detect Legionella pneumonia caused by non-L. pneumophila serogroup.

Geographical Analysis

North America is dominating the global legionella testing market.

North America dominated the global legionella testing market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the rising incidence of legionellosis and the presence of key players in the region. For instance, according to the Occupational Safety and Health Administration, around 6,000 Legionnaires' disease cases are reported annually in the United States. U.S. population-based study estimated that 8,000-18,000 people are hospitalized yearly with Legionnaires' disease. Furthermore, most market key players have a large portion of the global market, such as Becton, Dickinson and Company, Idexx Laboratories Inc., Phigenics LLC, Thermo Fisher Scientific Inc. and Abbott, ensure that North America commands the global legionella testing market. Moreover, North America has the most advanced and robust healthcare infrastructure and better healthcare cost reimbursement policies.

Competitive Landscape

The major players operating in the global legionella testing market are Albagaia Ltd, Aquacert Ltd, Becton, Dickinson and Company, BioMerieux SA, Idexx Laboratories Inc., Merck Millipore, Pacific Water Technology, Phigenics LLC, Abbott, Qiagen NV, and Thermo Fisher Scientific Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the legionella testing market globally. For instance, on February 23, 2022, Thermo Fisher Scientific Inc. and Moderna entered a long-term collaboration.

Abbott

Overview:

Abbott Laboratories is a leading American healthcare and medical devices innovator and producer headquartered in Illinois, United States, established in 1888. Abbott Laboratories is currently involved in dealing with medical devices, diagnostics, branded generic medicines and nutritional products.

Product Portfolio:

The product portfolio of Abbott for Legionella Testing has BINAX™ LEGIONELLA URINARY ANTIGEN EIA, Etc.

The global legionella testing report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Increasing Awareness
      • 4.1.1.2. Growing Research and Development Spending
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost Associated with Tests
      • 4.1.2.2. Strict Government Policies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type Segment
    • 7.1.2. Market Attractiveness Index, By Test Type Segment
  • 7.2. Urinary Antigen Test (UAT)
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Culture Methods
  • 7.4. Direct Fluorescent Antibody Test (DFA)
  • 7.5. Polymerase Chain Reaction (PCR)
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Clinical Testing Methods
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Environmental Testing Methods

9. By Antibiotics

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotics Segment
    • 9.1.2. Market Attractiveness Index, By Antibiotics Segment
  • 9.2. Azithromycin
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Rifampin
  • 9.4. Quinolones
  • 9.5. Others

10. By End-user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
    • 10.1.2. Market Attractiveness Index, By End-user Segment
  • 10.2. Hospitals
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic centers
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Abbott
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Albagaia Ltd
  • 13.3. Aquacert Ltd
  • 13.4. Becton, Dickinson and Company
  • 13.5. BioMerieux SA
  • 13.6. Idexx Laboratories Inc.
  • 13.7. Merck Millipore
  • 13.8. Pacific Water Technology
  • 13.9. Phigenics LLC
  • 13.10. Qiagen NV
  • 13.11. Thermo Fisher Scientific Inc.

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us